CS
AIMT

Credit Suisse’s Aimmune Therapeutics AIMT Stock Holding History

Credit Suisse’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-10,000
Closed -$273K – 4062
2018
Q3 		$273K Buy
+10,000
New +$283K ﹤0.01% 3565

Credit Suisse's AIMT Position: Q4 2020 in Review

Credit Suisse sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 536,076 shares — an estimated $18.5M sold.

Credit Suisse first reported a position in AIMT in Q3 2015 and held it in 20 quarters. The position peaked at $18.5M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

  • Credit Suisse reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Credit Suisse sold 536,076 Aimmune Therapeutics shares in Q4 2020, an estimated $18.5M.
  • Credit Suisse first reported a position in Aimmune Therapeutics in Q3 2015 and held it in 20 quarters.
  • Credit Suisse's Aimmune Therapeutics position peaked at $18.5M in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Credit Suisse's 13F filing for Q4 2020, filed 12 Feb 2021.